Corbus Pharmaceuticals is actively advancing a robust clinical pipeline of innovative therapeutic candidates targeting oncology and metabolic diseases. Its primary focus centers on next-generation pharmaceutical assets like CRB-701, an antibody-drug conjugate directed against Nectin-4 for advanced solid tumors, and CRB-913, a novel oral peripherally restricted CB1 inverse agonist designed for the safe treatment of obesity and metabolic disorders. Through disciplined clinical development and strategic global licensing agreements, the company continues to push multiple candidates through advanced human trials to address significant unmet medical needs.